Top Companies in the Ovarian Cancer Diagnostics and Therapeutics Market

The global ovarian cancer diagnostics and therapeutics market is projected to expand at a CAGR of 9.7% during the forecast period of 2024-2032.

Ovarian cancer is one of the leading causes of cancer deaths among women. As of the data published by the World Ovarian Cancer Coalition, the number of women suffering from ovarian cancer is expected to rise by almost 55% by 2050. Around 503,448 women around the world are expected to be diagnosed with the disease. Also, the number of women dying from ovarian cancer each year is projected to increase to 350,956, reflecting an increase of almost 70% from 2022. Additionally, the American Cancer Society has estimated that about 19,680 women will be diagnosed with ovarian cancer and nearly 12,740 women will die from it.

The market growth can be attributed to the rising number of FDA approvals. FDA approvals play a significant role in the regulatory practices of newly developed drugs. For instance, in June 2024, the FDA granted the antibody-drug conjugate (ADC) TUB-040 a fast-track designation for the treatment of patients with platinum-resistant high-grade ovarian cancer (PROC), demonstrating superior biophysical properties with durable responses. The designation is based on the results of a clinical trial in phase 1/2a NAPISTAR 1-01 study, which will increase FDA interaction with TIB-040 for developmental and further support to expedite the treatment to regulatory review, bringing high-risk patients closer to additional therapeutic options.

Additionally, in April 2024, the FDA approved mirvetuximab soravtansine-gynx (Elahere) to treat platinum-resistant ovarian cancer patients. Elahere is used to treat people with advanced, platinum-resistant ovarian cancer whose tumors produce an excessive amount of a protein called FR-a.

The increasing technological advancements in healthcare diagnostics play a major role in the early diagnosis of critical medical conditions. Integrating advanced technologies such as artificial intelligence and machine learning is revolutionising the diagnostics domain. For instance, in January 2024, scientists in the Georgia Tech Integrated Cancer Research Center (ICRC) developed a highly accurate early diagnostic test for ovarian cancer. They combined machine learning with blood metabolite data to develop the test with 93% accuracy among samples from the team’s study group. The high accuracy of the latest test is expected to increase the adoption among healthcare professionals to curate treatments and enhance patient outcomes. The new test is highlighting a promising new direction in the early detection of ovarian cancer, and other cancers either.

Top Companies Leading the Ovarian Cancer Diagnostics and Therapeutics Market in 2024

1.    AstraZeneca plc

AstraZeneca is a pharmaceuticals and biotechnology company with a portfolio of products for oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. AstraZeneca focuses on targeted therapies and precision medicine for ovarian cancer, including PARP inhibitors like Lynparza, enhancing treatment options and improving patient outcomes.

2.    C.H. Boehringer Sohn AG & Ko. KG

C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, founded in 1885. It is a leading pharmaceutical company with a significant focus on respiratory diseases, metabolism, immunology, oncology, and diseases of the central nervous system. Boehringer Ingelheim is involved in ovarian cancer research, focusing on innovative treatments and therapeutic approaches to improve survival rates and manage advanced stages of the disease.

3.    Bristol Myers Squibb Company

Bristol-Myers Squibb Belgium SA focuses on biopharmaceutical innovations, particularly in oncology. Bristol Myers Squibb offers immuno-oncology treatments for ovarian cancer, including checkpoint inhibitors, aiming to boost the immune system's ability to fight cancer cells effectively.

4.    Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical leader with a robust oncology portfolio. The company’s products include targeted therapies and immunotherapies. In the intratumoral cancer therapies market, Eli Lilly is developing localised treatment methods for its cancer drugs and, focusing on improving the efficacy of existing therapies and advancing new therapeutic approaches.

5.    F. Hoffmann-La Roche AG

Also known as Roche, it is a Swiss healthcare company focused on developing pharmaceuticals and diagnostics for the healthcare domain across the globe. Roche provides advanced diagnostics and targeted therapies for ovarian cancer, including the development of personalised medicine strategies and companion diagnostics to optimise treatment efficacy.